Related Experiment Video
Updated: May 20, 2026
09:42
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
Next-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis'
Peter Kraft1, Simon F De Meyer, Christoph Kleinschnitz
1Department of Neurology, University Clinic of Würzburg, Würzburg, Germany. kraft_p1@klink.uni-wuerzberg.de
Summary
Novel therapies targeting platelet receptors glycoprotein Ib alpha (GPIbα) and glycoprotein VI (GPVI) show promise for preventing ischemic stroke without increasing bleeding risk. The coagulation factor XII (FXII) pathway is also identified as a key thrombosis mediator.
Area of Science:
- Neuroscience
- Hematology
- Cardiovascular Medicine
Background:
- Current antithrombotic drugs for ischemic stroke have limitations, including moderate efficacy or increased hemorrhage risk.
- The precise roles of platelets and coagulation in stroke pathophysiology remain incompletely understood.
Purpose of the Study:
- To review recent advancements in understanding thrombus formation in ischemic stroke.
- To discuss the potential of novel therapeutic targets for stroke prevention.
Main Methods:
- Analysis of novel transgenic mouse models.
- Investigation of specific coagulation inhibitors.
- Detailed examination of molecular pathways in thrombus formation.
Main Results:
- Blocking platelet receptors GPIbα and GPVI prevents stroke without bleeding complications.
- Downstream signaling of GPIbα and GPVI is crucial for platelet activation and calcium homeostasis.
- Coagulation factor XII (FXII) is identified as a significant mediator of thrombosis in cerebrovascular disease.
Conclusions:
- Targeting platelet adhesion pathways offers a promising strategy for safe and effective ischemic stroke prevention.
- The intrinsic coagulation cascade, particularly FXII, represents a novel therapeutic target for cerebrovascular thrombosis.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:29Hemorrhagic Stroke ll: Pathophysiology
A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
01:15Ischemic Stroke ll: Pathophysiology
An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...